Psychedelics
October 1, 2026
Lorenzo Miller, Cordelia Kuiper Rauch, Keren Chen et al.
Background Psilocybin-assisted therapy has shown robust antidepressant effects among individuals with major depressive disorder (MDD); however, mechanisms of the treatment remain unclear. Depression has been associated with diminished feelings of connectedness to oneself, others, and the world, and psilocybin is thought to facilitate connectedness. This analysis of an open-label trial of...
Journal of Affective Disorders Reports
October 1, 2026
Kevin Byrne, Madeleine Odette, Eric L Garland et al.
ABSTRACT Background Healthcare workers experienced amplified depression and burnout during COVID-19. Both Mindfulness Based Stress Reduction (MBSR) and psilocybin have been shown to reduce depressive symptoms in this population, however the psychological mechanisms by which adding psilocybin to mindfulness training improves depression and trait mindfulness remain incompletely characterized....
International Journal of Innovative Technologies in Social Science
September 21, 2026
Mateusz Gawin, Emilia Koziara, Mateusz Gadzina et al.
Major depressive disorder (MDD) is one of the leading causes of disability worldwide. A substantial proportion of patients fail to achieve remission through standard monoaminergic therapies, meeting the clinical criteria for treatment-resistant depression (TRD). TRD is associated with significant clinical morbidity and a profound economic burden on healthcare systems. This review evaluates the...
npj Mental Health Research
September 16, 2026
Orly Lipsitz, Ryan M Brudner, Zoe Doyle et al.
Cluster B personality disorders (PDs) are highly comorbid with depression and are associated with attenuated antidepressant response. No clinical trials to date have reported on psilocybin-assisted psychotherapy (PAP) in comorbid treatment-resistant depression (TRD) and PDs. This is the first clinical trial to describe a subgroup of ten participants with a comorbid PD ( n = 9 cluster B; n = 1...
Frontiers in Psychiatry
September 15, 2026
Serena Chiara Civardi, Filippo Besana, Federico Durbano et al.
Background Treatment-resistant depression (TRD) is a major clinical challenge, with many patients failing to respond to conventional antidepressants. Psychedelic compounds such as psilocybin and ayahuasca have recently gained attention as potential rapid-acting therapies. Beyond their neurobiological effects, methodological, ethical, and real-world applicability concerns are critical for...
Orvosi hetilap
September 13, 2026
Szabolcs Kéri
Over the past five years, the literature on the psychiatric use of psychedelic and related treatments has expanded substantially. Several randomized controlled trials and pooled analyses have been conducted in mood disorders, treatment-resistant depression, and post-traumatic stress disorder. Trial methodology, however, remains a fundamental source of uncertainty, and despite the popularity of...
International Journal of Molecular Sciences
September 10, 2026
Xizhen Zhang, Xiaowen Zhang, Haiyu Zhang et al.
Depression, characterized by persistent low mood and anhedonia, represents a prevalent affective disorder imposing substantial medical and economic burdens. Current first-line antidepressants are limited by delayed onset and treatment resistance. Psilocybin (PSI) has re-emerged as a promising therapeutic agent with rapid, sustained antidepressant effects. This systematic review was conducted...
The International Journal of Neuropsychopharmacology
September 9, 2026
Sota Tomiyama, K Yonezawa, K Kusudo et al.
Abstract Background Cognitive dysfunction is associated with impaired psychosocial functioning in patients with major depressive disorder (MDD). Patients with treatment-resistant depression (TRD) exhibit more pronounced cognitive dysfunction than those with non-resistant MDD, underscoring the need for effective therapeutic strategies. Psilocybin has emerged as a promising treatment for...
The International Journal of Neuropsychopharmacology
September 9, 2026
Z Wang, W Chen, C Hu et al.
Abstract Background Within the rapidly expanding field of psychedelic research, psilocybin, along with its active metabolite psilocin, has emerged as a highly promising candidate in the search for innovative treatments for neuropsychiatric disorders. In this context, preclinical research using animal disease models has produced somewhat inconsistent results when employing standard tests to...
The International Journal of Neuropsychopharmacology
September 9, 2026
Lisa Harada, K Yonezawa, K Kusudo et al.
Abstract Background Despite sequential treatments with conventional antidepressants, many patients with depression experience insufficient clinical improvement, referred to as treatment-resistant depression (TRD). Psilocybin, a serotonergic psychedelic acting as a 5-HT2A receptor agonist, has attracted increasing attention as a novel treatment, with clinical trials demonstrating rapid and...